Your session is about to expire
← Back to Search
Atezolizumab-Based Combination Therapy for Prostate Cancer
Study Summary
This trial is testing a combination of immunotherapy and two other drugs to see if it is effective in treating localized prostate cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't taken any immune-boosting drugs in the last 4 weeks.This does not apply to me as it is an exclusion criterion.You need to have a tumor sample that is suitable for the study analysis, as determined by the study leader.I have previously been treated with specific immune therapies.You are pregnant or currently breastfeeding.I have had a previous transplant of stem cells or an organ.I have a condition that weakens my immune system.I have a serious heart condition.I need oxygen or steroids at home for my COPD.I have no health issues that prevent me from taking new medications.I am 18 years old or older.I have been treated with tocilizumab before.I have been treated with chemicals or radiation targeting my immune system.I have an active hepatitis B or C infection.I have not had a severe infection in the last 4 weeks.I have been treated with therapies that reduce cell counts before.I have had radiation therapy for prostate cancer.I need oral steroids for my asthma.I do not have nerve issues that could affect pain assessment.I am approved for and agree to undergo major prostate surgery.I have a history of specific lung conditions not caused by known factors.I am fully active or can carry out light work.My organs and bone marrow are working well.I have been on a stable blood thinner regimen for more than 3 months.I have had cancer before, but it was a specific type.I haven't had treatments like IVIG, plasmapheresis, or Prosorba in the last 6 months.My doctor has decided surgery is not an option for my prostate cancer.I have not received a live vaccine in the last 4 weeks.I have had a serious infection recently.My prostate cancer diagnosis was confirmed through a tissue examination.You are allergic to any of the study drugs or their ingredients.My scans show cancer has spread to other parts of my body.You have or have had a condition that affects your immune system.I have had treatment for prostate cancer.I do not have any uncontrolled serious illness affecting my organs.I haven't taken any immune-weakening drugs in the last 2 weeks.I have not had any treatment for prostate cancer.I have not had major surgery in the last 4 weeks.I have difficulty with IV access in my arms.My condition is considered high-risk.
- Group 1: Cohort A (atezolizumab)
- Group 2: Cohort B (atezolizumab, etrumadenant)
- Group 3: Cohort C (atezolizumab, tocilizumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are any additional participants needed for this clinical experiment?
"Affirmative, clinicaltrials.gov reveals that this medical trial is recruiting participants since its initial posting on October 30th 2019 and up to the most recent modification on October 8th 2022. It necessitates 68 patients from 3 sites for completion of the study."
What medical conditions is Tocilizumab usually prescribed to treat?
"Tocilizumab is widely used to manage small cell lung cancer (SCLC); however, it has also proven successful in treating systemic juvenile idiopathic arthritis (sjia), cytokine release syndrome caused by CAR-T Cell Therapy and malignant neoplasms."
Is this experiment the initial venture of its variety?
"At present, there are 410 ongoing clinical trials for Tocilizumab across 81 nations and 1798 cities. Hoffmann-La Roche was the first to conduct a trial with 720 participants back in 2008; since then, 304 have been concluded. This initial study made it through Phase 2 drug approval stage."
How many participants have signed up for this experiment so far?
"Correct. According to clinicaltrials.gov, this medical study is still recruiting patients; it was initially posted on October 30th 2019 and recently updated on October 8th 2022. A total of 68 participants are needed from the three designated sites."
Are there any additional investigations pertaining to Tocilizumab?
"Presently, there are 410 research studies examining Tocilizumab. Out of those 410 investigations, 78 are in Phase 3 and located mostly around Harvey, Illinois but with a total of 19515 sites running trials for this drug worldwide."
Is Tocilizumab considered a safe option for individuals?
"As this a Phase 2 trial, it is reasonable to assume that there has been some clinical data collected regarding the safety of Tocilizumab and thus it received a score of 2."
Share this study with friends
Copy Link
Messenger